SARS-CoV-2 (COVID-19 Virus) ResearchPublished on May 7, 2020
OET is currently helping COVID-19 research efforts by producing the recombinant spike glycoprotein of SARS-CoV-2 for clients. The protein will be used for further research, diagnostics and potential vaccine production.
OET is also engaged in in-house COVID-19 research and is working on an insect cell-based vaccine using our flashBAC system enabled through funding from Innovate UK/Department of Health through the Vaccines for Global Epidemics:development and manufacture initiative.
OET has recently received further funding from Innovate UK for their collaboration with Vaxine Pty Ltd for the development of a Covid-19 vaccine. Further details here.